During this segment, the panelists discuss how new agents have affected the expectations of physicians and patients in terms of overall outcomes. Unfortunately, they conclude that there is some disparity between the expectations and the reality.

Yehuda Handelsman, MD, FACP, FACE, FNLA, explains that our country has not achieved developing a multi-target agent. While certain drugs control certain events, they often lead to other events. Additionally, while treatment with agents such as glucagon-like peptide-1 is presented as a terrific treatment option, there is still a lack in data that demonstrates that it does in fact reduce cardiovascular disease.

Kenneth L. Schaecher, MD, FACP, CPC, agrees with Dr Handelsman but does feel that a benefit of the wide range of available agents has allowed professionals to treat patients with flexibility. Rather than treating a patient off of a specific protocol, this allows patients to be treated with a more personalized therapy concept.

Episode 16- Exploring the Benefits and Limitations of Available Agents

During this segment, Yehuda Handelsman, MD, FACP, FACE, FNLA, and Kenneth L. Schaecher, MD, FACP, CPC, discuss the availability of multiple agents to treat cardiometabolic disorders and explain their benefits and limitations.
Published Online: October 07, 2013
View More From This Discussion
Episode 1 Episode 1 - The Prevalence of Comorbid Cardiometabolic Disorders in the US
Episode 2 Episode 2 - The Challenges of Disease Management: Clinician and Provider Perspectives
Episode 3 Episode 3 - The Diversity of Patient Populations
Episode 4 Episode 4 - The Link Between Diabetes and Cardiovascular Disease
Episode 5 Episode 5 - Setting the Tone: Current Therapeutic Goals
Episode 6 Episode 6 - Diabetes and the Burden of Disease
Episode 7 Episode 7 - The Complex Equation of Management
Episode 8 Episode 8 - A Diverse Patient Population and Its Challenges
Episode 9 Episode 9 - Current Challenges and Gaps in Patient Care
Episode 10 Episode 10 - Drivers of Cost in Cardiometabolic Management
Episode 11 Episode 11- Future Outlook on Preventive Care
Episode 12 Episode 12- Comparing Current Healthcare Spending to Patient Outcomes
Episode 13 Episode 13- Current Developments of Pharmacotherapeutic Spending
Episode 14 Episode 14- Recent Trends in the Epidemiology of Cardiometabolic Conditions
Episode 15 Episode 15- Assessing the Factors at Increased Risk for Cardiometabolic Events
Episode 16 Episode 16- Exploring the Benefits and Limitations of Available Agents
Episode 17 Episode 17 - Evolving Guidelines for the Treatment of Cardiometabolic Events
Episode 18 Episode 18 - Impact of Obesity on Cardiometabolic Events
Episode 19 Episode 19 - - Initiatives Aim to Control Cardiometabolic Events
Episode 20 Episode 20 - Pharmacotherapeutic Initiatives
Episode 21 Episode 21 - Expectations for Newly Developing Agents
Episode 22 Episode 22 - Antiplatelet Agents Explored
Episode 23 Episode 23 - The Affordable Care Act and Healthcare Reform
Episode 24 Episode 24 - Accountable Care Organizations
Episode 25 Episode 25 - Closing Remarks